The gray market
“99% pure”: the lab number that became the whole sales pitch
The certificate arrives with the reassuring vocabulary of a laboratory: a large percentage, a colored graph, a test date, perhaps a badge promising that the product is independently verified. The number does not have to say “safe.” Its job is to make your brain finish the sentence.
“99% pure” is not a clinical verdict. Without its method, impurity profile and batch identity, the claim leaves open what was measured and what that measurement can support. The label lab tested can describe a genuine analysis and still leave the questions that matter to a person using the product unanswered. This is not an argument that laboratories cannot measure peptides. It is an argument about the distance between a measurement and a medicine.
The sample is the first limit
A report describes the material that reached the laboratory. Before its numbers can mean anything about a consumer’s container, someone has to connect that sample to a production batch, to the containers filled from it, and to what actually shipped.
That connection is not created by printing a lot number under a chart. The chain of custody matters: who selected the sample, what it represented, and whether the laboratory had any role beyond receiving it. A confident PDF from a real laboratory can still answer a much smaller question than the sales page asks it to settle.
Compare that with the development of an approved medicine. The ICH quality guideline describes specifications — tests, procedures and acceptance criteria — as one part of a larger control strategy: characterised material, suitable facilities, validated manufacturing, raw-material testing, stability work and a controlled manufacturing process. One percentage is not the system.
This is why a “lab tested” badge should not be read as an approval stamp. No regulator has approved Melanotan II as a tanning medicine because somebody published a certificate for it.
Five questions the magic number hides
Identity: what was in the measured sample? Checking purity and proving identity are not the same job. An identity claim needs a method and reference suited to that question. The 2012 systemic-toxicity case makes the distinction concrete: investigators used mass spectrometry against a purchased standard to confirm Melanotan II. That was meaningful evidence for that case. It was not a route to certifying an entire market.
Purity: a proportion of what? Synthesis can produce related impurities. Water, salts and other non-peptide material can also occupy part of a container. A percentage has to be read with its method, impurity profile and what was actually included in the denominator. Without that context, a bigger number is not automatically a better safety answer.
Content: how much is in this container? Purity and quantity are not synonyms. A sample can be described mostly in terms of a target molecule while the finished container’s actual fill remains a different question. This is not a semantic quibble: for a systemic drug, the amount in the product matters.
For the Melanotan II product they actually tested, Australia’s TGA made that distinction tangible. Investigators seized five nasal-spray bottles labelled “Pure Tans Triple Strength 30 MG.” Testing confirmed Melanotan II, but estimated 22 to 54 mg across the bottles, based on their labelled 20 mL volume. Identification did not make the printed amount consistent.
Sterility: is the finished preparation free from viable microorganisms? That requires separate microbiological assessment, with suitable processes and controls. A chemical analysis does not automatically supply that answer. The ICH guidance sets out specific sterility and endotoxin tests for parenteral new-drug products. That is what the approved-medicine specification has to address; it is not a finding that this unapproved market has those controls.
Handling: what happened after the instrument run? A sealed, recorded manufacturing process and a shelf-life programme are not the same as a powder moved through an opaque reselling chain. A result captured on one day is not a permanent description of everything subsequently shipped under the same picture.
What a broader assay can still miss
A study of a different peptide, semaglutide, illustrates why the questions have to stay separate. In Ashraf and colleagues’ 2024 investigation, three vials bought from illegal online sellers contained no viable microorganisms at the time of testing. Yet bacterial endotoxin — a different hazard — was detected in every vial. Measured purity was 7.7% to 14.37%, against 99% claims, and the semaglutide content exceeded the labelled amounts by 28.56% to 38.69%.
That study is not a survey of Melanotan II vials. It must not be turned into a pretend frequency estimate for them. Its value is as a controlled, analytical demonstration of the category error: a purity-only story can miss content, microbiology and endotoxin, and those omissions matter.
A Belgian screening of falsified peptide drugs, sampled from three suspected illegal internet pharmacies, found variations in unit content, peptide-related impurities, and elemental contamination. It tested other peptide and polypeptide drugs, not Melanotan II, and cannot estimate what fraction of the whole market contains them. It shows why a generic “peptide” claim is not a product-quality investigation.
The reasonable conclusion is neither that every certificate is forged nor that every vial contains poison. It is that a seller cannot substitute one attractive number for the strength and quality controls of an approved finished medicine.
The last gap is clinical
Imagine the strongest possible version of the paperwork: a genuine sample, handled correctly, tested with suitable methods, traced to the right containers. There is still no clinical conclusion about chronic Melanotan II use in that container. The chemical report does not assess melanocortin’s whole-body effects, the uncertain long-term record, or the changes in moles that warrant medical attention. Those belong on the side-effect ledger and in the mole problem.
Testing is not a ritual cancellation of pharmacology. A more carefully measured agonist would still be a systemic, non-selective agonist.
The gray market’s trick is the size of the inference. An analysis has a sample, a batch and a set of methods. A clinical product has a whole controlled history. Presenting the first as proof of the second sells the certificate’s wording and skips the chain between it, the container and the person…. truncated by the context compressor…
Common questions
What does '99% pure Melanotan II' mean?
It should refer to a purity result for the material actually tested, using a named method and specification. It does not, by itself, establish the identity or amount of peptide in every vial, whether the finished product is sterile, or whether using the unapproved drug is clinically safe.
Can a certificate of analysis prove Melanotan II is safe?
No. An analytical report can provide specific measurements about submitted material. It cannot supply the missing clinical trials on Melanotan II, and it cannot by itself bridge the gap between a laboratory sample and the finished, shipped container a consumer receives.
Are Melanotan II purity and dose the same thing?
No. Purity and quantity answer different questions. A result describing what proportion of measured material matches a target does not tell you how much material a container holds. Australia's TGA separately measured estimated contents of 22 to 54 mg in five seized nasal-spray bottles labelled 30 mg.